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Abstract—Two classes of 1,4-disubstituted 1,2,3-triazoles were synthesized using one-pot reaction of α-tosyloxy ketones/α-halo ketones, 
sodium azide, and terminal alkynes in the presence of aq. PEG (1:1, v/v) using the click chemistry approach and evaluated for Src kinase 
inhibitory activity. Structure-activity relationship analysis demonstrated that insertion of C6H5- and 4-CH3C6H4- at position 4 for both 
classes and less bulkier aromatic group at position 1 in class 1 contribute critically to the modest Src inhibition activity (IC50 = 32-43 µM) 
of 1,4-disubstituted 1,2,3-triazoles. 
                                                 
*
 Corresponding authors. Tel.: +91-1596-245073-279; Fax: +91-1596-244183;  
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Protein tyrosine kinases (PTKs) catalyze the 
phosphorylation of phenolic group of tyrosine residue in 
many substrate proteins by the transfer of γ-phosphate 
moiety of ATP. PTKs play a crucial role in the signal 
transduction pathways. The non-receptor tyrosine 
kinases of the Src family, Src, Yes, Lck, Fyn, Lyn, Fgr, 
Hck, Blk, and Yrk, share a great deal of structural 
homology and are present in the cytoplasm.1 Src 
tyrosine kinase plays a prominent role in regulating cell 
growth and differentiation. Src has been implicated in 
development of variety of cancers. Src mutations and/or 
overexpression has been correlated with tumor growth, 
metastasis, and angiogenesis.2  
 
Various structural motifs have been reported to target 
Src kinase3 such as quinolinecarbonitriles,4 ATP-
phosphopeptide conjugates,5 pyrazolopyrimidines,6 
purines,7 imidazo[1,5-a]pyrazines,8 benzotriazines,9 
pyrimidoquinolines,10 pyridopyrimidinones11, and 
quinazolines.12 Imatinib, a well known marketed PTK 
inhibitor, is used to treat a number of malignancies like 
chronic myelogenous leukemia (CML) and 
gastrointestinal stromal tumors (GISTs). Dasatinib is 
another marketed kinase inhibitor that inhibits Src 
family tyrosine kinases and BCR/ABL and is approved 
to use after Imatinib treatment. A 3-
quinolinecarbonitrile-based Src kinase inhibitor, 
Bosutinib, is undergoing rigorous trials for cancer 
treatment.13 
 
X-ray studies of phenylpyrazolopyrimidine inhibitors in 
Hck kinase-PP1 and Lck kinase-PP214 complexes have 
revealed a deep hydrophobic binding pocket near the 
ATP binding site of Src family kinases for the aryl 
moiety of the pyrazolopyrimidine template. We have 
previously shown that the hydrophobic interaction of 
the phenyl group with hydrophobic pocket is essential 
for the binding of 3-phenylpyrazolopyrimidines (Figure 
1) to the ATP binding site.15 The pyrazolopyrimidine 
core resembles the purine core of ATP itself and bind in 
the nucleotide binding site in the position normally 
occupied by the adenine base. Any substituent attached 
 to N1
 
of pyrazole occupies a mostly hydrophobic cavity 
in PP1. Most of this hydrophobic cavity remains 
unfilled. This cavity, in part, formed from side chains of 
helix αC and helix αD. 
 
 
Figure 1. Chemical structures of 3-phenylpyrazolopyrimidines and 1,4-
disubstituted 1,2,3-triazoles. 
 
Herein, we describe synthesis and evaluation of 1,4-
disubstituted 1,2,3-triazoles (Figure 1) as a novel 
template for Src kinase inhibition. The 1,2,3-triazoles 
are important heterocycles that are reported to possess 
several biological properties including anti-HIV,16 
antiallergic,17 antifungal,18 and antimicrobial,19 
activities. The 1,2,3-triazole based compounds have 
been previously reported to inhibit p38 MAP kinase and 
PfPK7 protein kinase.20   
 
We hypothesized that substitution at N1 and position 4 
of 1,2,3-triazoles with hydrophobic residues may 
occupy and interact with the hydrophobic binding 
pocket of Src ATP binding site similar to that of 3-
phenylpyrazolo-pyrimidines. The hydrophobic 
interactions of the hydrophobic groups with several 
amino acids in the hydrophobic pockets may contribute 
to the enhancement of potency. Furthermore, the 
attachment of hydrophobic group to 1,2,3-triazoles may 
generate novel geometric features that might contribute 
to binding of such compounds to Src kinase. 
 
Preparation of 1,2,3-triazoles (3a-z and 4a-m) has been 
widely explored using click chemistry approach due to 
its complete specificity, efficiency, simple reaction 
workup procedure, and quantitative reaction yield of the 
products.21 Furthermore, multicomponent reactions have 
been contributing considerably for the drug discovery 
by putting forth multiple arrays of compounds with 
diverse substitution patterns expeditiously.22 The 
synthetic strategy of these reactions can yield complex 
molecules with several new bonds and points of 
diversity in one pot thus alleviating the labor involved 
over a series of reaction workups.23  
 
The facile and eco-friendly synthesis of these 
derivatives involves a one-pot reaction of α-tosyloxy 
ketones/α-halo ketones, sodium azide, and terminal 
alkynes in the presence of aq PEG 400 (1:1, v/v) at 
room temperature under ‘Click’ conditions24 (Scheme 
1). The convenient preparation of 1,2,3-triazoles 
involves initial nucleophilic substitution reaction of α-
tosyloxy ketones/α-halo ketones with sodium azide to 
generate in situ α-azido ketones which is followed by 
Cu (I) catalyzed regioselective cycloaddition reaction 
with alkynes. The protocol is broadly applicable for the 
preparation of 1,2,3-triazoles as demonstrated by the use 
of various α-tosyloxy ketones/α-halo ketones (aliphatic, 
aromatic and cyclic) and alkynes (alkyl and aryl). Both 
the α-tosyloxy ketones and α-halo ketones reacted with 
almost the same efficiency. It was observed that the α-
tosyloxy ketones required marginally shorter reaction 
time when compared to α-halo ketones. Moreover, α-
tosyloxy ketones are ideal substitutes for the 
lachrymatory α-halo ketones. The mild reaction 
conditions and simple workup allowed us to rapidly 
prepare various substituted 1,2,3-triazoles in good 
yields (60-90%). After completion of the reaction, the 
contents were simply diluted with water, filtered, and 
dried to obtain 1,2,3-triazole which was finally 
recrystallized from ethyl acetate/hexane. The IR spectra 
of all the compounds exhibited a strong band at about 
1685 cm-1. In 1H NMR a characteristic singlet was 
observed for triazolyl C5–H at about δ 7.90 ppm. All the 
synthesized compounds were characterized by IR, 1H 
NMR, and mass spectroscopy.  
  
 
Scheme 1. Synthesis of 1,4-disubstituted 1,2,3-triazoles. 
 
Two classes of compounds with R1-CO(CH)- 
substitution at position 1 were synthesized using this 
procedure. The first class of compounds (3a-z) (Table 
1) includes 1,2,3-triazoles where R1 is a hydrophobic 
residue, such as phenyl, substituted phenyl, coumarinyl, 
2-thienyl, or other nonaromatic substituents (i.e., CH3, 
OCH3, N(C2H5)). In class 2 compounds (4a-m) (Table 
2), R1 is a cyclopentanone-2-yl, cyclohexanone-2-yl, or 
cycloheptanone-2-yl. The substitution at position 4 (R2) 
is phenyl, substituted phenyl, short alkyl, or a 
heteroaromatic (i.e., 2-pyridyl, 3-thienyl). The diversity 
of hydrophobic substitutions at R1 and R2 positions 
allowed the structure-activity relationship analysis of 
1,4-disubstituted 1,2,3-triazoles.  
 
An array of 39 diversely substituted 1,2,3-triazoles (20 
novel compounds) was evaluated against Src kinase. 
The results of Src kinase inhibitory activity of 
compounds in classes 1 and 2 are shown in Tables 1 and 
2, respectively.  
 
In general, the compounds in class 1 with R1 as 
nonaromatic alkyl groups (Me, N-ethyl, OMe, 3w-z) 
 exhibited weak Src kinase inhibition with IC50 values 
more than 100 µM or minimal inhibitory activity at 
highest concentration tested (375 µM). Furthermore, 
compounds with large aromatic groups such as styryl 
(3e), 3-coumarinyl (e.g., 3t, 3u) or aromatic groups with 
a bulky substitution (4-ClC6H4, 4-BrC6H4) in 3k-q 
showed weak Src inhibitory potency. Attempts to 
improve the activity by introducing an aliphatic 
substituent at R2 (3r, 3s) also resulted in poor inhibition, 
suggesting that the size of aromatic moiety at R1 
position is critical, and a bulky moiety at this position 
must be avoided. In contrast, the introduction of less 
bulkier unsubstituted phenyl and thienyl groups at 
position 1 in compounds 3b (IC50 = 41.6 µM) and 3v 
(IC50 = 32.5 µM) in class 1 significantly improved the 
Src inhibitory activities.  
 
The presence of an electron-donating methyl group in 
R1 and R2 phenyl ring in 3g (IC50 = 49.8 µM) did not 
result in improved inhibition when compared with 3b. 
The introduction of phenyl (3a), 4-F-3-CH3C6H3 (3c), 2-
pyridyl (3d), and n-butyl (3f) as R2 group drastically 
decreased the Src inhibitory activity versus 3b. 
Introduction of electronegative fluorine also did not 
improve the activity (3h, 3m, and 3q). These data 
indicate that the nature of R2 group contributes 
significantly to the overall activity.  
 
Table 1. The Src kinase inhibitory activities of 1,2,3-triazoles 3a-z (class 
1). 
 
Compds R1
 R2
 IC50 (µM)a 
3a C6H5 C6H5 >100.0 
3b C6H5 4-CH3C6H4 41.6 
3c C6H5 4-F-3-CH3C6H3 81.0 
3d C6H5 2-pyridyl NA
b
 
3e Styryl C6H5 >100.0 
3f C6H5 n-butyl NA 
3g 4-CH3C6H4 4-CH3C6H4 49.8 
3h 4-CH3C6H4 4-F-3-CH3C6H3 82.3 
3i 4-OCH3C6H4 C6H5 >100.0 
3j 4-OCH3C6H4 3-CH3C6H4 72.8 
3k 4-ClC6H4 C6H5 139.0 
3l 4-ClC6H4 4-CH3C6H4 108.7 
3m 4-ClC6H4 4-FC6H4 NA 
3n 4-ClC6H4 4-OCH3C6H4 NA 
3o 4-ClC6H4 3-thienyl >150.0 
3p 4-BrC6H4 4-CH3C6H4 NA 
3q 4-BrC6H4 4-FC6H4 NA 
3r 4-BrC6H4 n-butyl NA 
3s 4-BrC6H4 1-Cl-butan-4-yl >100.0 
3t coumarin-3-yl C6H5 89.5 
3u coumarin-3-yl 4-CH3C6H4 >150.0 
3v 2-thienyl C6H5 32.5 
3w CH3 C6H5 >150.0 
3x CH3 4-CH3C6H4 >150.0 
3y OCH3 C6H5 >100 
3z N(C2H5) C6H5 >150.0 
Staurosporine _ _ 0.3 
PP2 _ _ 2.8 
aThe concentration of the compound that inhibited enzyme activity by 
50%; bless than 10% enzyme inhibitory activity was observed up to the 
concentration of 75 µM. 
In order to explore the effect of nonaromatic cyclic 
functional groups at R1 position in Src inhibitory 
activity, a series of analogs 4a-m having different cyclic 
ketones and bearing nonaromatic groups at R1 position 
were prepared and evaluated (Table 2). Compounds 4g 
and 4h with N1 2-cyclohexanone and C4 phenyl/tolyl 
groups exhibited modest Src kinase inhibition with IC50 
values of 43.2 and 33.9 µM, respectively. Introduction 
of 4-fluorophenyl, 4-methoxyphenyl and 3-thienyl 
substituents at C4 position of 1,2,3-triazole also led to 
the compounds (4c, 4d, 4e, 4i, 4j, and 4k) with poor 
activity. Other compounds in class 2 showed diminished 
activity versus 4g and 4h, confirming the importance of 
R2 groups in overall activity. Compound 4h (IC50 = 33.9 
µM), a modest Src kinase inhibitor, was selected for 
inhibitory selectivity assays against Lck, a member of 
Src family kinase, EGFR, a receptor tyrosine kinase, 
and Csk, a tyrosine kinase that phosphorylates Src. IC50 
values in all cases were >100 µM (See, Figure S1, 
Supplementary Data). These data suggested that 
compound 4h was selective against Src when compared 
with the selected kinases. 
 
Table 2. The Src kinase inhibitory activity of compounds 4a-m  
(class 2). 
 
Compds R1
 R2
 IC50 (µM)a 
4a cyclopentan-1-on-2-yl C6H5 105.5 
4b cyclopentan-1-on-2-yl 4-CH3C6H4 62.1 
4c cyclopentan-1-on-2-yl 3-thienyl NAb 
4d cyclopentan-1-on-2-yl 4-OCH3C6H4 NA 
4e cyclopentan-1-on-2-yl 4-FC6H4 NA 
4f cyclopentan-1-on-3-yl C6H5 NA 
4g cyclohexan-1-on-2-yl C6H5 43.2 
4h cyclohexan-1-on-2-yl 4-CH3C6H4 33.9 
4i cyclohexan-1-on-2-yl 3-thienyl NA 
4j cyclohexan-1-on-2-yl 4-FC6H4 NA 
4k cyclohexan-1-on-2-yl 4-OCH3C6H4 NA 
4l cyclohexan-1-on-3-yl C6H5 NA 
4m cycloheptan-1-on-2-yl 4-CH3C6H4 66.1 
aThe concentration of the compound that inhibited enzyme activity by 
50%; bless than 10% enzyme inhibitory activity was observed up to the 
concentration of 75 µM. 
 
Molecular modeling was utilized to examine how the 
structures would fit within the ATP binding site of the 
enzyme (Figure 2). The modeling studies indicated that 
tolyl groups in 3b and 4h occupy the hydrophobic 
binding pocket similar to tolyl group of PP1 with 
slightly different orientations (Figure 2). The 
substitution at N1 position of triazole occupied mostly 
the hydrophobic cavity of Src ATP binding site similar 
to that of t-butyl group of PP1. The compounds 
demonstrated only modest inhibitory potency possibly 
 because of mostly hydrophobic interactions. The 4-
amino group of PP1 and PP2 is hydrogen bonded to the 
side chain of Thr338 as well as the carbonyl of Glu339 
that contributes significantly to their potency as Src 
kinase inhibitors. 
 
 
 
Figure 2. Comparison of structural complexes of Src kinase with 
different 1,2,3-triazoles (3b, red; 4h, green) and PP1 (blue) based on 
molecular modeling. The compounds are rendered in stick styles. They 
are the lowest energy conformers predicted for the compounds. 
 
In summary, compounds 3b, 3g, 3v, 4g, and 4h 
exhibited modest Src kinase inhibitory activity among 
the synthesized 1,2,3-triazoles with IC50 values in the 
range of 32-43 µM. Comparison of moderately active 
compounds indicate that the insertion of C6H5- and 4-
CH3C6H4- at R2 position in both groups with appropriate 
less bulkier group at R1 position in class 1 is well 
tolerated for the modest Src inhibition activity of 1,2,3-
triazoles. The structure-activity relationship data 
provide insights for further optimization of this scaffold 
and/or use in fragment-based discovery of Src kinase 
inhibitors.  
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